A better test for the tumor-targeting of CAR-T therapies

November 06, 2020

NOVEMBER 06, 2020, NEW YORK - Ludwig Cancer Research scientists have developed a method to significantly improve the preclinical evaluation of chimeric antigen-receptor (CAR) T cell therapies, in which the immune system's T cells are extracted from a patient, engineered to target a specific tumor-associated molecule and then grown and reinfused for cancer treatment. Published in the Journal of Experimental Medicine, the study also reports the construction and evaluation of co-engineered CAR-T cells and applies the method to examine their effects on tumors in a mouse model of the skin cancer melanoma.

Though CAR-T therapies have been approved for blood cancers, their application to solid tumors has proved challenging. This is in part because the complex microenvironments of solid tumors dampen immune responses in a variety of ways, not least through the recruitment of various suppressive immune cells.

"Most of the studies on CAR-T therapies have been done using human T cells in mice that lack their own immune system--because if they had one, it would attack the human CAR-T cells," said Melita Irving, a researcher at the Ludwig Institute for Cancer Research Lausanne Branch who led the study with Ludwig Lausanne Director George Coukos. "But the tumor microenvironment can have a huge impact on your T cell product, so we're really interested in doing studies using engineered mouse T cells in immunocompetent mice. This allows us to observe the dynamic interplay between the immune system and the CAR-T cells that we transfer."

The trouble is that mouse T cells are difficult to engineer and expand optimally in culture in the numbers required to rigorously model CAR-T cell therapies. For the current study, the Ludwig Lausanne team first developed a protocol to overcome those difficulties. It involved, among other things, the sequential use of three immune signaling molecules known as interleukins (IL-2, 7 and 15) in the cultivation and expansion of the engineered T cells.

They showed that CAR-T cells cultured using the protocol are markedly activated when exposed to their target. The cells also show signs of being more youthful and have molecular features common to memory T cells that grow briskly when stimulated by their targets.

"This means that when you transfer these cells, they're very robust cells and can really expand quickly to control tumors," said Irving.

Irving, Coukos and colleagues then engineered their cultured mouse T cells to co-express, along with the chimeric antigen receptor, the IL-15 protein--which promotes the formation of memory T cells. They then examined the efficacy of these "fourth generation" (4G) CAR-T cells against a mouse model of melanoma and compared their activity to that of ordinary mouse CAR-T cells generated using the novel protocol.

"We saw better tumor control by the IL-15 expressing CAR-T cells and better proliferation and persistence of the CAR-T cells themselves," said Irving. The 4G CAR-T cells were also less prone to programmed cell death and expressed lower levels of a cell surface protein named PD-1, which promotes T cell suicide.

Their analysis revealed that the 4G CAR-T cells were not just killing cancer cells more efficiently. They were also reprogramming the microenvironment of the tumor to augment such killing. Their use resulted in an activation of natural killer cells--which target cancer cells--in the tumor microenvironment, and a marked decline in M2 macrophages, which suppress anti-tumor immune responses and support tumor growth.

"We hope that our publication of this protocol will help the T cell engineering community in general and enable a more robust preclinical evaluation of T cell therapies," said Irving.
This study was supported by Ludwig Cancer Research, the European Research Council, the Biltema Foundation and Oncosuisse.

In addition to his Ludwig post, George Coukos directs the Department of Oncology at the University Hospital of Lausanne (CHUV-UNIL) and co-directs the Swiss Cancer Center, Léman. Melita Irving is also a group leader within the department of oncology, UNIL CHUV.

About Ludwig Cancer Research

Ludwig Cancer Research is an international collaborative network of acclaimed scientists that has pioneered cancer research and landmark discovery for nearly 50 years. Ludwig combines basic science with the ability to translate its discoveries and conduct clinical trials to accelerate the development of new cancer diagnostics and therapies. Since 1971, Ludwig has invested $2.7 billion in life-changing science through the not-for-profit Ludwig Institute for Cancer Research and the six U.S.-based Ludwig Centers. To learn more, visit http://www.ludwigcancerresearch.org.

For further information please contact
Rachel Reinhardt
rreinhardt@lcr.org or

Ludwig Institute for Cancer Research

Related Cancer Treatment Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

A new treatment for liver cancer
In the latest issue of Molecular Therapy, Skoltech and MIT researchers have published a new combinatorial therapy for the treatment of liver cancer.

Cancer cell reversion may offer a new approach to colorectal cancer treatment
A novel approach to reverse the progression of healthy cells to malignant ones may offer a more effective way to eradicate colorectal cancer cells with far fewer side effects, according to a KAIST research team based in South Korea.

NUS researchers show potential liver cancer treatment by targeting cancer stem-like cells
NUS researchers from the Cancer Science Institute of Singapore and the N.1 Institute for Health have shown the potential use of small molecule inhibitors to treat advanced liver cancer.

Breast cancer gene a potential target for childhood liver cancer treatment
Hepatoblastoma is a rare liver cancer that mainly affects infants and young children and is associated with mutations in the β-catenin gene.

Light therapy could replace opioids as main treatment for cancer treatment side effect
A worldwide coalition of researchers and clinicians has agreed that light therapy is among the most effective interventions for the prevention of oral mucositis, painful ulcers in the mouth resulting from cancer therapy.

Scanning for cancer treatment
11,000 people are predicted to die from acute myeloid leukemia (AML) in 2019.

Visualizing better cancer treatment
Researchers have engineered nanoscale protein micelles capable of both delivering chemotherapeutic drugs and of being tracked by MRI.

Read More: Cancer Treatment News and Cancer Treatment Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.